TAVEXIA logo

Tavexia Lifecare Ltd

TAVEXIA · BSE 539519 · Retail

₹1.14−₹0.010.87%Prev. close ₹1.15
At close: 17 Nov 2026, 3:30 PM India time · NSE
Market cap
₹44 Cr
P/E (last FY)
114.00
Forward P/E
—
Open
₹1.14
Day range
₹1.14 – ₹1.17
52W range
₹0.49 – ₹1.25
EPS (last FY)
₹-0.06
Dividend yield
0.00%
Volume
2.46 L
P/B
1.02
ROE
0.5%
Debt / equity
0.08

P/B is the price over the book value per share at Sept 2026.

Dividend yield is the cash dividends of the last 12 months over the price, restated for any split or bonus.

News

Financials

Earnings

Valuation

Ownership

Business

Technicals

Your research

Tavexia Lifecare Ltd (TAVEXIA): company summary

The company's revenue surged 513.1% annually, but net profit collapsed 91.6% year-on-year.

Tavexia Lifecare Ltd (TAVEXIA) is a micro-cap Retail company valued at ₹44 crore operating in Distributors on the NSE and BSE.

Recent price move
Tavexia Lifecare Ltd last traded at ₹1.14, modestly down 0.87% on the day.
Recent developments
On 2026-06-30, the company reported a net profit loss of ₹0 crore for the latest quarter, reversing a profit of ₹1 crore in the same quarter a year earlier. The company's revenue for the latest quarter was ₹1 crore, down from ₹1 crore in the prior year's quarter. The company's annual net profit fell to ₹0 crore, down from ₹2 crore in the previous year.
Financial performance
The company's revenue surged 513.1% annually, but net profit collapsed 91.6% year-on-year. The latest quarter saw revenue fall 47.5% compared to the same quarter a year earlier, while net profit swung from a profit of ₹1 crore to a loss of ₹0 crore.
Valuation multiples
The stock trades at 114.0 times earnings, 1.02 times book value.
Things to watch
The company's net profit margin plummeted to 0.7% from 47.3% a year ago, indicating severe deterioration in profitability. The latest quarter showed a net profit loss of ₹0 crore, reversing a profit of ₹1 crore in the same quarter a year earlier. The stock is 7.2% below its 52-week high, reflecting a significant decline from recent peak levels.
Where it stands
The company's revenue growth has been robust, but profitability has deteriorated sharply, with net profit turning negative in the latest quarter. The stock is trading at 7.2% below its 52-week high, and the net profit margin has collapsed to 0.7%. The most significant movement is the shift from a profit to a loss in the latest quarter.

Summarised by DocStoX's model on 2026-11-15 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.

TAVEXIAFree with a DocStoX account

Tavexia Lifecare Ltd peers in Consumer Discretionary

Other Consumer Discretionary stocks on the NSE & BSE. See the full Consumer Discretionary sector list.